Dr. Robert A. Ramirez, D.O.
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 22
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 224
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
TN license 1992 -
Hematology & Oncology Physician
LA license DO.000292 · TN license 1992 -
Internal Medicine Physician
TN license 1992
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Vanderbilt University Medical Center Nashville, TN
- Vanderbilt Wilson County Hospital Lebanon, TN
Medical groups
- Vanderbilt Health Clinicians, LLC (129 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 224
- Services billed
- 569
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 240 | 137 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 58 | 22 |
| New patient office or other outpatient visit, 60-74 minutes | 49 | 49 |
| Established patient office or other outpatient visit, 40-54 minutes | 34 | 31 |
| Hospital discharge day management, 30 minutes or less | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Creon (lipase/protease/amylase) Other prescribers in Nashville, TN | 32 |
| Promethazine Hcl Other prescribers in Nashville, TN | 22 |
| Oxycodone Hcl Other prescribers in Nashville, TN | 21 |
| Tagrisso (osimertinib mesylate) | 20 |
| Ondansetron Hcl Other prescribers in Nashville, TN | 20 |
| Prochlorperazine Maleate Other prescribers in Nashville, TN | 18 |
| Morphine Sulfate Er (morphine sulfate) Other prescribers in Nashville, TN | 17 |
| Octreotide Acetate | 15 |
| Prednisone Other prescribers in Nashville, TN | 15 |
| Xermelo (telotristat etiprate) | 15 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 11 payments worth $5,991 in total to this clinician.
| Tersera Therapeutics LLC | $3,541 |
|---|---|
| Exelixis Inc. | $1,800 |
| AstraZeneca Pharmaceuticals LP | $300 |
| Curium US LLC | $291 |
| Novartis Pharmaceuticals Corporation | $37.85 |
| AbbVie Inc. | $20.47 |
| Consulting Fee | $3,430 |
|---|---|
| Honoraria | $1,800 |
| Food and Beverage | $461 |
| Compensation for services other than consulting (speaking, faculty) | $300 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Tersera Therapeutics LLC Oct 22, 2025 | Consulting Fee Xermelo · Oncology | $3,430 |
| Exelixis Inc. Dec 12, 2025 | Honoraria CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $1,800 |
| AstraZeneca Pharmaceuticals LP Jan 27, 2025 | Compensation for services other than consulting (speaking, faculty) IMFINZI · Oncology Company’s descriptionSpeaker Fee | $300 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $465,759 in research payments for these studies, mostly to the institutions running them.
- A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan MK-6482, formerly PT2977 Monotherapy in Participants with Advanced Pheochromocytoma,Paraganglioma PPGL, Pancreatic Neuroendocrine Tumor pNET, von Hippe…
Merck Sharp & Dohme LLC - Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
E.r. Squibb & Sons, L.l.c. · Active, not recruiting · NCT05477576 - A Phase Ib Dose Finding Study Assessing Safety and Activity of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Extensive Stage Small Cell Lung Cancer (ES-SCLC) in Combination With Carboplatin, Etoposide and Tislelizumab in Ind…
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.